Capricor Stock Rallies 20% on DMD Data Presentation Update
Avidity Gets FDA Partial Clinical Hold Lifted on DM1 Drug Candidate
Peering Into Dyne Therapeutics's Recent Short Interest
Dyne Therapeutics(DYN.US) Director Sells US$4.34 Million in Common Stock
$Dyne Therapeutics(DYN.US)$ Director Kersten Dirk sold 120.24K shares of common stock on Sep 20, 23, 2024 at an average price of $36.07 for a total value of $4.34 million.Source: Announcement What
Dyne Therapeutics to Present at Chardan's 8th Annual Genetic Medicines Conference
Piper Sandler Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $53
Piper Sandler analyst Edward Tenthoff maintains $Dyne Therapeutics(DYN.US)$ with a buy rating, and maintains the target price at $53.According to TipRanks data, the analyst has a success rate of 31.3%